British Journal of Medical & Surgical Urology
Volume 2, Issue 5 , Pages 185-190 , September 2009

The decline of TURP—An Irish experience

Received 3 August 2008 ,Revised 7 May 2009 ,Accepted 13 May 2009.

References 

  1. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol. 2005;173(April (4)):1256–1261
  2. Hollingsworth JM, Wei JT. Economic impact of surgical intervention in the treatment of benign prostatic hyperplasia. Rev Urol. 2006;8(Suppl. 3):S9–S15
  3. McNicholas TA. Management of symptomatic BPH in the UK: who is treated and how?. Eur Urol. 1999;36(Suppl. 3):33–39
  4. Sharma DP. The management of benign prostatic obstruction: a voice from the Third World. BJU Int. 2006;97(April (4)):671–672
  5. Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol. 1975;47(April (2)):193–202
  6. O’Leary MP. Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications. Urology. 2003;62(September (3 Suppl. 1)):15–23
  7. Littlejohn JO, Ghafar MA, Kang YM, Kaplan SA. Transurethral resection of the prostate: the new old standard. Curr Opin Urol. 2002;12(January (1)):19–23
  8. Wilson JR, Urwin GH, Stower MJ. The changing practice of transurethral prostatectomy: a comparison of cases performed in 1990 and 2000. Ann R Coll Surg Engl. 2004;86(November (6)):428–431
  9. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)—incidence, management, and prevention. Eur Urol. 2006;50(November (5)):969–979[discussion 80]
  10. Gyomber D, Lawrentschuk N, Ranson DL, Bolton DM. An analysis of deaths related to urological surgery, reviewed by the State Coroner: a case for cardiac vigilance before transurethral prostatectomy. BJU Int. 2006;97(April (4)):758–761
  11. Wendt-Nordahl G, Bucher B, Hacker A, Knoll T, Alken P, Michel MS. Improvement in mortality and morbidity in transurethral resection of the prostate over 17 years in a single center. J Endourol. 2007;21(September (9)):1081–1087
  12. Chirikos TN, Sanford E. Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia. J Urol. 1996;155(April (4)):1311–1316
  13. Canadian Coordinating Office for Health Technology Assessment. Cost-Effectiveness and Cost-Utility Analyses of Finasteride Therapy for the Treatment of Benign Prostatic Hyperplasia. Ottawa O, Canada: CCOHTA; 1995.
  14. DiSantostefano RL, Biddle AK, Lavelle JP. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia. BJU Int. 2006;97(May (5)):1007–1016
  15. Foley CL, Taylor C, Kirby RS. Counting the cost of treating benign prostatic hyperplasia. BJU Int. 2004;93(February (3)):250–252
  16. Sweet R, Kowalewski T, Oppenheimer P, Weghorst S, Satava R. Face, content and construct validity of the University of Washington virtual reality transurethral prostate resection trainer. Urology. 2004;172(November (5 Pt 1)):1953–1957
  17. O’Loughlin R, Allwright S, Barry J, Kelly A, Teljeur C. Using HIPE data as a research and planning tool: limitations and opportunities. Ir J Med Sci. 2005;174(April–June (2)):40–45[discussion 52–7]
  18. Krautschick AW, Kohrmann KU, Henkel TO, Michel MS, Alken P. Interstitial laser coagulation in benign prostatic hyperplasia: a critical evaluation after 2 years of follow-up. Urol Int. 1999;62(2):76–80
  19. Hoffman RM, MacDonald R, Slaton JW, Wilt TJ. Laser prostatectomy versus transurethral resection for treating benign prostatic obstruction: a systematic review. J Urol. 2003;169(January (1)):210–215
  20. Emberton M, Fitzpatrick JM. The Reten-World survey of the management of acute urinary retention: preliminary results. BJU Int. 2008;101(Mar (Suppl. 3)):27–32[review]
  21. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998;338(February (9)):557–563
  22. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med. 1996;335(August (8)):533–539
  23. Rosette Jdl, Collins E, Bachmann A, Choi B, Muir G, Reich O, et al. Historical aspects of laser therapy for benign prostatic hyperplasia. Eur Urol Suppl. 2008;7(April (4)):363–369

PII: S1875-9742(09)00090-1

doi: 10.1016/j.bjmsu.2009.05.003

British Journal of Medical & Surgical Urology
Volume 2, Issue 5 , Pages 185-190 , September 2009

Article Tools

* Image Usage & Resolution